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Abstract
Accumulating evidence indicates that angiotensin-converting enzyme 2 (ACE2) plays a crit-
ical role in cardiovascular homeostasis, and its altered expression is associated with major
cardiac and vascular disorders. The aim of this study was to evaluate the regulation of vas-
cular function and assess the vascular redox balance in ACE2-deficient (ACE2-/y) animals.
Experiments were performed in 20–22 week-old C57BL/6 and ACE2-/y male mice. Evalua-
tion of endothelium-dependent and -independent relaxation revealed an impairment of in
vitro and in vivo vascular function in ACE2-/y mice. Drastic reduction in eNOS expression at
both protein and mRNA levels, and a decrease in •NO concentrations were observed in aor-
tas of ACE2-/y mice in comparison to controls. Consistently, these mice presented a lower
plasma and urine nitrite concentration, confirming reduced •NO availability in ACE2-defi-
cient animals. Lipid peroxidation was significantly increased and superoxide dismutase
activity was decreased in aorta homogenates of ACE2-/y mice, indicating impaired antioxi-
dant capacity. Taken together, our data indicate, that ACE2 regulates vascular function by
modulating nitric oxide release and oxidative stress. In conclusion, we elucidate mecha-
nisms by which ACE2 is involved in the maintenance of vascular homeostasis. Further-
more, these findings provide insights into the role of the renin-angiotensin system in both
vascular and systemic redox balance.
Introduction
The prevalence of cardiovascular diseases is one of the major public health problems [1]. The
interplay in the triad renin-angiotensin system (RAS), endothelial function (EF), and oxidative
stress plays a key role in cardiovascular and metabolic homeostasis and, thus, in the pathogene-
sis of these diseases [2,3].
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Angiotensin-Converting Enzyme 2 (ACE2), a zinc metalloprotease, is an important compo-
nent of the RAS [4]. It catalyzes the conversion of angiotensin II (Ang II) to angiotensin-(1–7)
(Ang-(1–7)). Therefore, it determines the balance between the vasoconstrictor/pro-oxidative
peptide Ang II, which is originally produced by ACE and acts via its receptor AT1, and the
vasodilatory/antioxidative peptide Ang-(1–7), which interacts with its receptor Mas [5,6]. Con-
sequently, the ACE2/Ang-(1–7)/Mas axis represents a protective arm of the RAS, which coun-
teracts deleterious actions of the ACE/Ang II/AT1 axis. Accordingly, altered expression and/or
activity of ACE2 have been associated with major cardiac and vascular pathophysiologies.
ACE2-deficient mice exhibit a higher susceptibility to atherosclerosis [7–9], diabetic nephropa-
thy [10,11], myocardial infarction [12], and cardiac hypertrophy [13–16].
The vascular endothelium is a dynamic and pleiotropic tissue, which synthesizes and
releases autacoids. The maintenance of EF is crucial for cardiovascular homeostasis. The
release of nitric oxide (•NO) plays a pivotal role in EF, mediating the crosstalk between endo-
thelium and smooth muscle cells. Oxidation of •NO by superoxide anion (•O2
-) and conse-
quent formation of peroxynitrite (-ONOO) is discussed to be an important factor contributing
to the development of endothelial dysfunction [2]. Furthermore, one of the pivotal hallmarks
of cardiovascular and metabolic diseases, including hypertension, diabetes, atherosclerosis,
stroke, and heart failure, is reduction-oxidation (redox) imbalance, a condition, known as oxi-
dative stress [17].
Numerous studies have shown that oxidative stress plays an important role in the develop-
ment of endothelial dysfunction [2,3,5]. We have previously shown that Mas-deficiency results
in an imbalance between •NO and reactive oxygen species (ROS) [18,19]. This oxidative stress
contributes to both endothelial dysfunction and elevated blood pressure observed in Mas-defi-
cient mice on two different genetic backgrounds, C57BL/6 and FVB/N [18,19]. In line with
these observations, increased endothelium-dependent relaxation in response to acetylcholine
(ACh) in vitro and improved EF in vivo has been observed in a transgenic rat model, overex-
pressing human ACE2 in vascular smooth muscle cells (VSMC) [20].
Collectively, these data suggest that the ACE2/Ang-(1–7)/Mas axis plays an important role
in maintaining EF and vascular homeostasis. Whereas the adverse cardiovascular effects in
ACE2-deficient mice have been partly explained by an impaired EF and an oxidative/nitrosa-
tive imbalance [7,21,22], the molecular mechanisms linking ACE2, ROS and •NOmetabolism
remain poorly understood. The aim of the present study was to evaluate the effect of genetic
deletion of ACE2 on in vivo vascular function and on ROS and •NO generating and degrading
factors in C57BL/6 mice.
Materials and Methods
Animals and treatment protocols
The animal procedures were performed conforming the guidelines from the Directive 2010/63/
EU of the European Parliament on the protection of animals used for scientific purposes and
the experiments performed for this manuscript were approved (study number G0066/04) by
the Landesamt für Gesundheit und Soziales (LAGeSo), Berlin. Euthanasia was performed using
an overdose of inhalable anesthetics. Mice were maintained in individually ventilated cages
(IVC), 34×19×13 cm (Tecniplast1 S.p.A., Hohenpeissenberg, Germany) under a 12 hr light/
dark cycle, with lights on at 6 am, with free access to standard chow (0.25% sodium, SSNIFF1
Spezialitäten, Soest, Germany) and drinking water ad libitum. The colony of ACE2-deficient
mice on C57BL/6 genetic background [4] was maintained by breeding homozygous ACE2-de-
ficient females (ACE2-/-) with hemizygous males (ACE2-/y). Independent cohorts of 20–22
week-old ACE2-/y and age matched C57BL/6 control (WT) male mice were used for the
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following experiments: evaluation of in vivo endothelial function; metabolic cages, including
urine collection, blood sampling, and organ collections for the biochemical analysis. Basic
blood pressure and heart rate were measured by radiotelemetry as described before [19].
Evaluation of endothelial function in conscious mice
EF was measured in vivo as presented elsewhere [19,20]. Briefly, the animals were anesthetized
using isoflurane as described above and catheters were implanted using aseptic technique.
After control hemodynamic measurements (PowerLab1, ADI Instruments Co., Colorado
Springs, CO, USA), the endothelium-dependent response was tested by administration of
increasing doses of acetylcholine (ACh, Sigma-Aldrich1, Seelze, Germany) (25/ 50/ 100/ 200
ng.kg-1), followed by a single dose of sodium nitroprusside (SNP, Sigma-Aldrich1, Seelze, Ger-
many) (10 μg.kg-1) in conscious mice. EF was calculated by the normalization of the ACh
response by the SNP response according to the formula: EF = ΔMAP (ACh).ΔMAP (SNP)-1
[19,20].
Euthanasia and organ collection
To collect the urine, mice were individually housed in metabolic cages (Tecniplast1 S.p.A.,
Hohenpeissenberg, Germany) for up to 72h with food and water available ad libitum. After 48
hours of acclimatization, 24h urine was collected, volume was measured gravimetrically, and
the samples were stored at -80°C until further analysis.
Blood samples were collected under ketamine/xylazine anesthesia (100 mg.kg-1 ketamine,
10 mg.kg-1 xylazine, ip) via cardiac puncture from the right ventricle. Blood was aspirated
directly into syringes rinsed with 0.2 M Ethylene Diamine Tetraacetic Acid (EDTA), trans-
ferred into prechilled EDTA-coated tubes (Fischer Scientif1, Schwerte, Germany) and centri-
fuged (4,000 rpm) at 4°C for 10 minutes. Plasma was transferred to the new tube and kept at
-80°C until the analysis. Mice were dissected immediately after the blood draw. Collected tis-
sues were snap-frozen in liquid nitrogen and stored at -80°C until analysis of protein expres-
sion and oxidative/nitrosative-redox balance.
Isometric contractions of mouse vessels
Male wild-type C57BL/6 and ACE2-/y mice (25–30 g, 8–12 weeks) were killed under isoflurane.
The thoracic aortas were removed, quickly transferred to cold (4°C), oxygenated (95% O2 / 5%
CO2) PSS (in mmol.L
-1: 119 NaCl, 4.7 KCl, 1.2 KH2PO4, 25 NaHCO3, 1.2 Mg2SO4, 11.1 glu-
cose, and 1.6 CaCl2) and dissected into 2 mm rings whereby perivascular fat and connective tis-
sue were removed. Each ring was positioned between two stainless steel wires (diameter 0.0394
mm) in a 5 mL organ bath of a Mulvany Small Vessel Myograph (DMT 610 M; Danish Myo
Technology, Denmark). The organ bath was filled with PSS. The bath solution was continu-
ously oxygenated with a gas mixture of 95% O2 and 5% CO2, and kept at 37°C (pH 7.4). The
rings were placed under tension of 0.3 g [23]. The software Chart5 (AD Instruments Ltd.
Spechbach, Germany) was used for data acquisition and display. The rings were precontracted
with 60 mmol.L-1 KCl and equilibrated until a stable resting tension was acquired. Vessels were
pre-constricted with 1 μmol.L-1 phenylephrine, followed by the determination of ACh- or
SNP-induced relaxations (3–3000 nmol.L-1). Drugs were added to the bath solution if not indi-
cated otherwise. The magnitude of relaxation caused by ACh or SNP was expressed as the per-
centage of the isometric contraction evoked by phenylephrine, which was taken as 100%.
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Measurement of plasma nitrite levels, total nitrate and nitrite urine
excretion rate
Total nitrate and nitrite urinary excretion rate (NOx) was determined using a commercially
available kit (Cayman Chemical1, Ann Arbor, MI, USA) and normalized to creatinine concen-
tration (mg.dL-1) (Labtest1, Belo Horizonte, Brazil). The levels of nitrite in plasma were mea-
sured as described previously (Xu et al., 2008).
Measurement of nitric oxide anion (•NO) release produced by aortic
segments in response to ACh
Mice were euthanized with a mixture of ketamine/xylazine and thoracic aortas were rapidly
removed and cut into ring segments ~2.5–3 mm long, with care taken not to injure the endo-
thelium. To estimate vascular •NO production, we used diaminofluorescein (DAF-FM)
enhanced fluorescence (excitation 495 nm and emission 515 nm; TECAN1 Infinite 200 PRO
plate reader, Männedorf, Switzerland) in the darkness. Briefly, each aortic segment was placed
in an individual well of cell culture dishes (24-well) containing 2.0 mL of Krebs-HEPES buffer
(in mmol.L-1: NaCl 99; KCl 4.7; MgSO4 1.2; KH2PO4 1.0; CaCl2 1.9; NaHCO3 25; glucose 11.1,
NaHEPES 20; pH 7.4) supplemented with 2 mmol.L-1 L-arginine, in a light-protected humidi-
fied chamber at 37°C for 30 minutes. Following the initial equilibration, basal fluorescence was
recorded for 20 minutes. Subsequently, the aortas were reincubated in the same buffer supple-
mented with the 5 μmol.L-1 DAF-FM (Sigma-Aldrich1, Seelze, Germany) for 45 minutes. The
measurement of •NO release in response to ACh (10 μmol.L-1) was performed on 2 separate
rings for 3 minutes. To ensure the specificity of the method the assay was also performed in the
presence of L-NAME (100 μmol.L-1, Sigma-Aldrich1, Seelze, Germany). The amount of
released •NO was expressed as arbitrary units per mg of aortic protein [24].
Evaluation of aortic protein expression by Western blot
After collection and removal of adipose and connective tissue, aortas were pulverized in liquid
nitrogen. The pulverized samples were suspended in lysis buffer (pH 7.5; Cell Signaling Tech-
nology1, Beverly, MA) containing 50 mmol.L-1 Tris-HCl, 0.1 mmol.L-1 EDTA, 0.1 mmol.L-1
EGTA, 0.1% SDS, 0.1% deoxycholate, 1% IGEPAL, and a 1000-fold dilution of a mammalian
protease and phosphatase inhibitor cocktail (Roche1, Mannheim, Germany). The suspension
was centrifuged at 14,000 rpm for 20 min. Total protein levels were determined by the Bradford
assay [24]. Equal amounts of protein were loaded and transferred to polyvinyl difluoride mem-
branes. Western blots were performed using commercially available antibodies for eNOS,
phosphorylated Ser1177-eNOS, HSP90, AKT, phosphorylated AKT, and β-actin (Dilution:
1:1000, 1:1000, 1:500, 1:1000, 1:500, and 1:1000, respectively) (Cell Signaling Technology1,
Beverly, MA). After binding of corresponding fluorescent secondary antibodies (Li-COR1
Biosciences, Lincoln, USA), protein levels were detected and analyzed by Odyssey1 IR scanner
(Li-COR1 Biosciences, Lincoln, USA).
Real-time quantitative PCR
Total RNA was extracted from aorta (TRIzol1 Reagent, Germany) and 1 μg was reverse- tran-
scribed using M-MLV (Invitrogen1, Paisley, United Kingdom) to cDNA. The reaction product
was amplified by real time quantitative PCR on the 7900HT Fast System using the GoTaq
qPCRMaster Mix (Promega1, Mannheim, Germany). For all mRNA quantification GAPDH
was used as an internal reference. The expression levels were obtained from the cycle threshold
(Ct) associated with the exponential growth of the PCR products. Quantitative values for
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mRNA expression were obtained by the parameter 2 −ΔCt, in which ΔCt represented the sub-
traction of the GAPDH Ct values from the others. Specific fragments were amplified using fol-
lowing primers. eNOS: forward, 5´ CGT CCT GCA AAC CGT GCA GA; reverse, 5´TCC TGG
GTG CGC AAT GTG AG. SOD1: forward, 5’ GAC GGT GTG GCC AAT GTG TC; reverse, 5’
CAA GCG GCT CCC AGC ATT TC. SOD2: forward, 5’ GCG GTC GTG TAA ACC TCA
ATA ATG; reverse, 5’ CCA GAG CCT CGT GGT ACT TCT C. UCP-2: forward, 5´GCA TTG
GCC TCT ACG ACT CT; reverse, 5´GCT CTG GTA TCT CCG ACC AC. GAPDH: forward,
5´ CCA TCA CCA TCT TCC AGG AG; reverse, 5´GTG GTT CAC ACC CAT CAC AA.
Arginase activity
Arginase activity was determined by quantitating urea production using a spectrophotometric
method as described previously [25]. In brief, 50 μL of filtered aorta homogenate were added to
75 μL of Tris-HCl (50 mmol plus 10 mmol MnCl2; pH 7.5) into a 2-mL reaction tube. The con-
tents were then mixed and heated at 55°C for 10 min for enzymatic activation. After this step,
components of the reaction were incubated with 50 μL of the substrate L-arginine (0.5 M, pH
9.7) at 37°C for 60 min. To stop the reaction, 400 μL of an acid solution (H2SO4-H3PO4-
H20 = 1:3:7) were added to the tube. Finally, for the development of the chromogen, 25 μL of
α-isonitrosopropiophenone (9% in ethanol) were added, and the mixture was heated at 100°C
for 45 min. The urea levels were determined by measuring absorbance at 550 nm (TECAN1
Infinite 200 PRO plate reader, Männedorf, Switzerland) and normalized by protein concentra-
tion [24]. The data were expressed as nmol.L-1 urea per mg protein.
In situ detection of vascular •O2
− release
Superoxide anion (•O2
-) production in cryosections of mouse aorta was detected using the fluo-
rescent probe dihydroethidium (DHE) in a procedure described previously with slight modifi-
cations [26,27]. Shortly, fresh segments of upper descending thoracic aorta were frozen in
Tissue-Tech1 OCT compound, cryosectionned into 7 μm thick sections, mounted on a glass
slide, and stored at -80°C until analysis. For the experiments, the tissue sections were incubated
with Krebs-HEPES buffer for 30 minutes at 37°C with or without 500 U.mL-1 polyethylene gly-
col-conjugated superoxide dismutase (PEG-SOD; Sigma-Aldrich1, Seelze, Germany). Then,
fresh buffer containing 2 μmol.L-1 DHE (Molecular ProbesTM, Invitrogen1, Paisley, United
Kingdom) was applied topically onto each tissue section and incubated for another 30 minutes
in a light-protected humidified chamber at 37°C. Images were obtained using a LEICA DM-
2500 laser scanning confocal microscope equipped with a krypton/argon laser using identical
acquisition settings. For each aortic ring, mean fluorescence was calculated from 3 separate
high-power fields. Mean data for the quantification of fluorescence were expressed as intensity
per mm2
Lipid peroxidation
Lipid peroxidation was determined by measuring the ThioBarbituric Acid-Reactive Substances
(TBARS), as a marker of systemic oxidative stress assayed by malondialdehyde (MDA), in
aorta homogenate, plasma, and urine, as described by Ohkawa et al. [28]. In parallel, MDA
standards were diluted in the range of 0–4 μmol.L-1. TBARS values were expressed in nmol.
mL-1 MDA equivalents. Absorbance was read at 532 nm (TECAN1 Infinite 200 PRO plate
reader, Männedorf, Switzerland) and normalized by protein concentration [24].
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Aortic concentrations of hydrogen peroxide
Hydrogen peroxide (H2O2) concentrations in aorta homogenates were determined by fluores-
cence in black microplates (Nunclon1 Surface, Thermo Fisher Scientific1, Vantaa, Finland),
using the Amplex1 UltraRed Hydrogen Peroxide (10-acetyl-3,7-dihydroxiphenoxazine) Assay
(Invitrogen1, Paisley, United Kingdom). This reagent, in the presence of peroxidase (horsered-
ish peroxidase, HRP), stoichiometrically reacts with H2O2 to form a red-fluorescent oxidation
product, resorufin. A standard curve of H2O2 was prepared by dilution into reaction buffer,
with concentrations ranging from 0 to 10 μmol.L-1. Next, 50μL from the prepared curve points
or from the aorta homogenate samples (or plasma) were plated in duplicate, with the addition
of 50μL of working solution/HRP for beginning the reaction. The microplates were incubated
at room temperature for 120 minutes, protected from light, and read at wave lengths of 530 nm
and 590 nm for excitability and emission, respectively, in a microplate reader (Tecan 200 Infi-
nite1 200 PRO plate reader, Männedorf, Switzerland).
Vascular enzymatic antioxidant status
Superoxide dismutase (SOD) and glutathione peroxidase (GPx) activity in aorta homogenates
were measured with specific assay kits (Fluka1 and Cayman Chemical1, Seelze, Germany, and
Ann Arbor, MI, USA, respectively) according to the protocols provided by the manufacturers.
Catalase activity in aorta homogenate was measured spectrophotometrically as described else-
where [19]. All data were normalized by protein concentration [24].
Data Analysis
Results are expressed as mean ± SEM, and "n" indicates the number of animals used in the
experiment. The dose-response curves of the different groups were compared by two way
ANOVA followed by Bonferroni’s correction. For simple comparisons between 2 groups, an
unpaired Student’s t test was used where appropriate using GraphPad Prism1 version 5.0 for
Windows. A value of P<0.05 was considered significant.
Results
ACE2-deficient mice exhibit in vivo vascular dysfunction
To clarify the physiological role of ACE2 in blood pressure regulation, we first performed
radiotelemetric recordings in conscious ACE2-/y male mice. Mean arterial pressure was mod-
estly (~7 mmHg), but significantly elevated in ACE2-/y mice in comparison to WTmice (Fig
1A). In contrast, heart rate was not affected by ACE2 deletion (Fig 1B).
To evaluate if ACE2-deficiency affects vascular function, we investigated the vascular reac-
tivity in vivo in conscious ACE2-/y mice by bolus intra-aortic administration of the endothe-
lium-dependent vasodilator acetylcholine (ACh). This mode of ACh application does not
reduce the heart rate of the animals (S1 Fig), since ACh is degraded before reaching cardiac
rhythm generators, and has been used before by our group to evaluate endothelial function in
vivo in mice [19] and rats [20]. The vasodilatory response to ACh did not differ between
ACE2-/y and WTmice over the dose range of 50 to 200 ng.kg-1 (Fig 1C). In contrast, the endo-
thelium-independent response, elicited by SNP, was drastically increased in ACE2-/y mice (Fig
1D), arguing for an adaptation mechanism in the vascular smooth muscle cells. Normalization
of the ACh response to the SNP revealed impairment in endothelium-dependent vascular reac-
tivity in ACE2-/y mice (Fig 1E), indicating that genetic deletion of ACE2 may result in a novel
equilibrium with an impaired endothelial release of vasodilators and an increased smooth mus-
cle response to these substances.
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We could also confirm these data in vitro using aortic rings of ACE2-/y and WTmice. While
ACh-induced relaxation was unaffected in the ACE2-deficient vessels, SNP elicited a more
potent effect at lower doses in ACE2-/y aortas (Fig 1F and 1G).
ACE2-deficiency leads to reduced •NO bioavailability
We next tested if •NO levels are affected by ACE2-deficiency. Determination of nitrite and
nitrate (NOx), stable •NOmetabolites, in body fluids is widely used as a marker of •NO produc-
tion [29]. Both plasma nitrite concentration (Fig 2A) and the urinary NOx excretion rates
Fig 1. Vascular function in ACE2-/y mice.Mean arterial pressure (A) and heart rate (B) were measured by
radiotelemetry in ACE2-/y andWT (n = 6) mice. Data represent means±SEMs of 3 days of recording.
**P<0.01. Vascular response to increasing concentrations [50–200 μg.kg-1] of ACh (C) and 10 μg.kg-1 SNP
(D) in ACE2-/y (n = 5) andWT (n = 6) mice. (E) Vascular response to ACh normalized by SNP. Data represent
means±SEMs. **P<0.01 (Student t test); §§ P<0.01 (2-way ANOVA). Similar data were obtained in 2
independent experiments. (F) ACh and (G) SNP dose-response curve of aortic rings from ACE2-/y (KO,
n = 8–10) andWT (n = 13) mice. Rings were precontracted with phenylephrine (1 μmol.L-1) and then stepwise
relaxed with ACh or SNP (3–3000 nmol.L-1). *P<0.05.
doi:10.1371/journal.pone.0150255.g001
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Fig 2. Nitric oxide availability and eNOS expression in ACE2-/y mice. Plasma nitrite content (A) and
24-hour urinary excretion (B) of nitrate plus nitrite (NOx) in ACE2-/y (n = 6) andWT (n = 6) mice. (C) eNOS
activity, evaluated by •NO release in aorta rings upon application of ACh (DAF-FM bioassay) (ACE2 n = 5;
WT n = 6). (D) arginase activity in aorta homogenates of ACE2-/y (n = 6) andWT (n = 6) mice. Representative
western blot and densitometric analysis of eNOS (E) and phosphorylated Ser1177-eNOS (F) protein levels in
thoracic aortas from ACE2-/y (n = 5) andWT (n = 5) mice. (G) Relative expression of phospho-eNOS
normalized to the total eNOS levels. (H) eNOSmRNA expression levels (real time PCR analysis). Data are
expressed as mean ± SEM. *P<0.05, **P<0.01, **P<0.001, Student’s t test.
doi:10.1371/journal.pone.0150255.g002
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(Fig 2B) were markedly decreased in ACE2-/y mice in comparison to WT animals. These results
indicate that •NO production is impaired in ACE2-deficient mice.
eNOS is the main source of plasma •NO. To evaluate eNOS activity, we next investigated
•NO release in vitro in aortic segments of ACE2-/y mice. ACh-induced •NO release was
decreased in ACE2-/y mice compared to WT animals (Fig 2C). This effect was blunted by the
eNOS inhibitor L-NAME (Fig 2C). To exclude the possibility that the decrease in •NO produc-
tion was due to an altered activity of arginase, an enzyme which competes with NOS isoforms
for the same substrate, L-arginine, we also measured activity of this enzyme. No significant dif-
ference was found in total arginase activity (Fig 2D) between ACE2-/y and WTmice, arguing
that decrease in the •NO production was due to a reduction in eNOS activity.
eNOS activity is regulated by phosphorylation at multiple sites. Therefore we evaluated the
phosphorylation status of eNOS in ACE2-/y mice. Both the amount of total eNOS protein and
eNOS phosphorylated at the activation site Ser1177 (Fig 2E and 2F) were significantly decreased
in aortic tissue of ACE2-/y compared toWTmice, whereas the relation between P-eNOS Ser1177
and total eNOS was unaffected by ACE2-deficiency (Fig 2H). Moreover, eNOS mRNA expression
was reduced in aorta of ACE2-/y mice, further confirming a downregulation of eNOS expression
evoked by the lack of ACE2. The HSP90 (Fig 3A), AKT (Fig 3B), P-AKT (Fig 3C), and P-AKT/
AKT ratio (Fig 3D) remained unchanged between strains, suggesting that the impairment in •NO
generation observed in ACE2-/y mice is driven by AKT-independent pathways.
Taken together, our findings showed that ACE2 deficiency results in the reduction of •NO
bioavailability due to the downregulation of the eNOS expression.
ACE2-deficiency results in increased oxidative stress
•NO is a known antioxidant, which provides a protective function against ROS action by
quenching •O2
−. We hypothesized that reduced •NO availability may contribute to the
increased oxidative stress in ACE2-/y mice. Indeed, evaluation of lipid peroxidation, which is
an indicator of oxidative stress, revealed a significant increase in the levels of the TBARS, mal-
ondialdehyde (MDA), in plasma, urine, and aorta of ACE2-/y mice (Fig 4A–4C). Also direct
measurement of the •O2
- release in the aorta showed an elevation in oxidative stress in ACE2-/y
mice in comparison to WT animals (Fig 4D). However, ACE2 deletion did not affect aortic
concentrations of H2O2 (Fig 4E), a
•O2
- dismutation product generated by superoxide dismut-
ase (SOD). Analysis of enzymes involved in ROS metabolism showed a significant decrease in
both total SOD and catalase activity in aorta of ACE2-/y mice (Fig 4F and 4I, respectively). Con-
currently, the mRNA levels of SOD1 (Fig 4G), but not SOD2 (Fig 4H) and catalase (Fig 4J)
were lower in ACE2-/y than in WT mice. Interestingly, under similar experimental conditions,
the aortic glutathione peroxidase (GPx) activity in ACE2–/y mice was ~2-fold higher than that
of WT animals (Fig 4K).
Since enhanced oxidative stress was observed in aorta of ACE2-/y mice, we analyzed the
expression of uncoupling protein 2 (UCP2), an inner-mitochondrial key regulator of intracellular
ROS, by real-time PCR analysis using total RNA from aorta tissue. ACE2 deletion induced a sig-
nificant decrease in UCP2mRNA levels (Fig 4M), compared with the control animals. In con-
trast, the expression of other isoforms of UCP, UCP1 and UCP3, were not changed (Fig 4L–4N).
Together, these results suggest that oxidative stress observed in ACE2-/y mice is mainly
caused by inefficient antioxidation and scavenging of ROS.
Discussion
ACE2 is a monocarboxypeptidase, whose main function in the RAS is the degradation of the
proinflammatory and vasoconstrictor peptide, Ang II, and the generation of Ang-(1–7), which
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is known to counterbalance the actions of Ang II [18]. We took advantage of a mouse model
with genetic deletion of ACE2 to address the role of this enzyme in the regulation of the bal-
ance between •O2
- and released •NO within the endothelial environment which is pivotal in the
maintenance of vascular homeostasis [18,30]. The major finding of the present study demon-
strated the establishment of a novel equilibrium in the vascular wall of in ACE2-deficient mice
through processes associated with increased aortic oxidative stress and decreased •NO release.
In our study, we have shown that genetic ablation of ACE2 in mice on a C57BL/6 genetic
background leads to a small but significant elevation in blood pressure, which is probably the
result of vascular dysfunction. These data are consistent with a previous study showing increase
in blood pressure in ACE2-/y mice on C57BL/6 background [31], but does not concur with
other studies in different mouse strains [4,31,32]. Other groups may have missed the small
change in blood pressure due to the mixed genetic background, high variability of the blood
Fig 3. AKT expression in ACE2-/y mice.Representative western blots and densitometric analysis of HSP90
(A), AKT (B) and P-AKT (C) aortic protein levels. (D) P-AKT/AKT ratio. Results are representative of four to
six separate experiments. Data are expressed as mean ± SEM.
doi:10.1371/journal.pone.0150255.g003
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Fig 4. Oxidative stress and ROS degrading enzymes in ACE2-/y mice.Concentration of the TBARS
malondialdehyde (MDA) in plasma (A), urine (B), and aorta (C) of ACE2-/y (n = 5) andWT (n = 5) mice. (D)
Representative fluorescent photomicrographs (left) and quantification (right) showing in situ detection of ⚫O2
-
by confocal microscopy (7 μm sections of thoracic aorta). Aortic sections were labeled with the oxidative dye
dihydroethidium (2 μM/L), which is oxidized to EtBr in the presence of ⚫O2
- and gives red fluorescence. High
EtBr fluorescence was found in aortic walls of ACE2-/y mice, whereas the signal was almost undetectable in
aortas of WT animals. (n = 5–6). (E) H2O2 levels in aorta of ACE2
-/y mice. Activity (F, I) and mRNA expression
by real time PCR (G, H, J) of ROS degrading enzymes, SOD (F, G, H) and catalase (I, J) in aorta of ACE2-/y
(n = 4) andWT (n = 5) mice. (K) aorta GPx activity. mRNA expression level of UCP1 (L), UCP2 (M), and
UCP3 (N) in aorta of ACE2-/y mice. *P<0.05, **P<0.01 (Student t test).
doi:10.1371/journal.pone.0150255.g004
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pressure data and a lack of statistical power. The potential reasons for these discrepant results
have been comprehensively discussed [33]. Interestingly, the backcross of the ACE2-null allele
to the FVB/N background led to a more dramatic blood pressure upregulation in the resulting
animals (our unpublished data), similar to the phenotype observed in Mas-deficient mice on
the C57BL/6 [5] and on the FVB/N [19] backgrounds, suggesting a protective role of the
C57BL/6 background in blood pressure regulation.
Interestingly, the vascular dilatation induced by bolus intra-aortic injections of increasing
doses of ACh was not altered in ACE2-deficient mice, despite that a drastic reduction in •NO
bioavailability was observed. However, the response to the endothelium independent vasodila-
tor, SNP, was enhanced in ACE2-/y mice, pointing to an adaptation process happening under
chronic removal of ACE2. These in-vivo observations were reproduced in vitro in isolated aor-
tic rings and are, therefore, not caused by any systemic alterations in these mice. Probably, the
altered SNP-response of the smooth muscle layer is induced by the chronic reduction in eNOS
activity in ACE2-deficient animals, since a similar phenomenon was observed in eNOS-defi-
cient mice: SNP induced a markedly greater accumulation of cGMP in aortic rings of these ani-
mals compared to controls [34]. The underlying molecular mechanisms, however, remained
elusive but involved an increased activity of soluble guanylate cyclase.
In this study we observed a drastic reduction in •NO availability in ACE2-/y mice, which was
obvious from a reduced •NO release from intact aortic rings and a strong decrease in urinary
concentration of NOx and plasmatic nitrite in ACE2-deficient mice. Nitrite serves as an indi-
rect indicator of endothelial •NO release, and is reduced also in humans with endothelial dys-
function [29]. According to our data, these reduced levels of •NO in ACE2-/y mice are due to
two different effects of ACE2 depletion: a reduction in active eNOS and an inactivation of •NO
by ROS. On one hand, the amount of phosphorylated eNOS at Ser1177, which modulates both
the calcium sensitivity and activity of the enzyme, was significantly reduced in ACE2-/y mice
compared to control animals. Since ACE2 deletion did not alter the AKT pathway, the decrease
in eNOS activity must be regulated by AKT-independent mechanisms [35] and could at least
partially be explained by its lowered expression level, whereby the mechanisms leading to this
downregulation of eNOS expression need further elucidation. On the other hand, increased
oxidative stress observed in ACE2-deficient mice may lead to the depletion of BH4 [36], a
cofactor essential for the coupling of eNOS, and thereby shift the balance between •NO and •O2
generation by eNOS to the favor of the second [37,38], further decreasing •NO levels and
increasing ROS production in these mice. eNOS uncoupling is an important mechanism lead-
ing to pathologic •O2
- release in the vascular endothelium, which induces decline in •NO avail-
ability. Quick oxidative inactivation of •NO by •O2
-, and consequent formation of -ONOO, a
potent oxidant [39], plays a pivotal role in the development of endothelial dysfunction [40].
These events are associated with an increase in lipid peroxidation, as we observed in the present
study by monitoring increased systemic and aortic TBARS levels. Increased superoxide and
peroxynitrite levels have also recently been found by other groups in ACE2-/y mice at baseline
or after Ang II infusion and have been linked to increased NADPH oxidase activity [41,42].
The increased ROS levels observed in ACE2-/y mice can be also caused by a reduction in
antioxidant capacity in these animals. This hypothesis is supported by a significant reduction
in aortic SOD and catalase activity in ACE2-/y mice, enzymes, which inactivate •O2
- [39]. and
convert H2O2 to molecular oxygen and water [43]., respectively. These results are in accor-
dance with those previously demonstrating that exogenous SOD improves the endothelium-
dependent vascular relaxation response to ACh at basal conditions [44]. Moreover, increasing
vascular SOD activity induces a significant improvement in arterial relaxation in cholesterol-
fed rabbits [45]. Unexpectedly, the levels of H2O2 in aorta were similar in both strains. This
may perhaps be due to the increase of GPx and the decrease of catalase activities in the aortas
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of ACE-/y mice, which counterbalance each other and normalize the H2O2 levels, since both
enzymes are responsible for H2O2 degradation [43,46].
It has been shown that UCP2, an inner-mitochondrial key regulator of intracellular ROS,
preserves endothelial function in obese diabetic mice [47] and prevents salt-sensitive hyperten-
sion [48] by promoting the increase in •NO bioavailability and suppressing ROS production. In
agreement with these previous findings, our data demonstrate that ACE2 null mice show a sig-
nificant decrease in UCP2 mRNA levels in aorta which may directly contribute to the increase
in •O2
- and decreased •NO bioavailability and, consequently, to endothelial dysfunction.
Accordingly, UCP2 upregulation was recently observed in isolated endothelial cells overexpres-
sing ACE2 [49].
Taken together, our current work provides strong evidence for a disturbance of the oxida-
tive/nitrosative balance in ACE2-deficient mice. Concurrently, Bodiga and colleagues [14]
showed an exaggerated increase in •O2
- production, probably by NAD(P)H oxidase following
pressure-overload induced by aortic constriction in ACE2-/y mice. The authors showed that
Ang-(1–7) delivery by mini-osmotic pumps decreases the NAD(P)H oxidase activity and
improves the early dilated cardiomyopathy in pressure-overloaded animals. Jin et al. [39],
showed that endothelial dysfunction induced by Ang II infusion is exaggerated in ACE2-defi-
cient mice mainly by hyperactive ROS generation. In hypertensive rats, overexpressing human
ACE2 in VSMC endothelium-dependent relaxation increased in response to ACh in both, in
vitro and in vivo conditions [20]. Furthermore, we and others [49,50] recently showed that
pharmacological activation of ACE2 ameliorates endothelial dysfunction in hypertensive and
diabetic animals. In two different mouse models lacking Mas, a central component of ACE2/
Ang/(1–7)/Mas axis, we have shown that the increase in local and systemic oxidative stress,
observed in these mice, was strongly correlated with in vivo endothelial dysfunction [19].
Hence, our and other reports show that the ACE2/Ang-(1–7)/Mas arm of the RAS regulates
endothelial function by modulating the oxidative stress and •NO release balance.
Several studies have previously shown that •NO is a potent and central mediator of several
physiopathological processes involved in cardiovascular regulation [18,39,51,52]. Moreover, a
number of studies in patients with cardiovascular diseases have described a close relationship
between imbalance of vascular •NO and ROS concentrations and endothelial dysfunction
[52,53]. Hypertensive patients have been reported to have significantly higher levels of plasma
lipid peroxidation when compared with normotensive subjects [54]. Accordingly, plasma
MDA, an index of lipid peroxidation, was significantly and positively correlated with endothe-
lial dysfunction in both humans [51,55] and animal models [19,56]. Thus, it is conceivable that
in hypertension and other cardiovascular diseases an imbalance between the protective ACE2/
Ang-(1–7)/Mas arm, and the deleterious ACE/AngII/AT1 axis of the RAS induces a significant
reduction in •NO bioavailability associated with oxidative stress and causes endothelial
dysfunction.
In conclusion, we elucidate mechanisms by which ACE2 is involved in the maintenance of
vascular homeostasis. Furthermore, these findings provide insights into the role of the RAS in
both vascular and systemic redox balance. Therefore, the ACE2/Ang-(1–7)/Mas axis is a poten-
tial target for the development of novel cardiovascular protective and/or antioxidant drugs.
Supporting Information
S1 Fig. Heart rate before and after treatment of ACE2-/y and WTmice with ACh [50–
200 μg.kg-1] and 10 μg.kg-1 SNP by injection in the descending aorta. There is no direct car-
diodepressive effect by ACh on the heart but even at some doses a slight increase in heart rate
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after injection probably induced by the baroreflex. P<0.05 (paired t test).
(PDF)
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